Charles Heise, Associate Director, Bioprocess Strategy & Development, FUJIFILM Biotechnologies

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.